Evidence map›Paper›PMID 32916609›Full record

ArticleAmerican heart journal2020

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.

Donna H Ryan, Ildiko Lingvay, Helen M Colhoun, John Deanfield, Scott S Emerson, Steven E Kahn, Robert F Kushner, Steve Marso, Jorge Plutzky, Kirstine Brown-Frandsen and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in American heart journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03574597. Cited by 109 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 3 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03574597 phase3completed

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Ran2018Enrolled17,604Registered outcomes29Posted comparisons1ConditionsObesity, OverweightArmsPlacebo (semaglutide), semaglutide
PMID 33567185PMID 37952131other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 3 syntheses or guidelines pooled it, 235 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 4 countries.

Donna H RyanPennington Biomedical Research Center, Baton Rouge, LA.
Ildiko LingvayDepartment of Internal Medicine/Endocrinology and Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX.
Helen M ColhounInstitute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
John DeanfieldFarr Institute of Health Informatics Research at London, London, UK; National Institute for Cardiovascular Outcomes Research, University College London, London, United Kingdom.
Scott S EmersonDepartment of Biostatistics, University of Washington, Seattle, WA.
Steven E KahnVA Puget Sound Health Care System and University of Washington, Seattle, WA.
Robert F KushnerDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Steve MarsoHCA Midwest Health Heart and Vascular Institute, Kansas City, MO.
Jorge PlutzkyCardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Kirstine Brown-FrandsenNovo Nordisk A/S, Søborg, Denmark.
Marianne O L GronningNovo Nordisk A/S, Søborg, Denmark.
G Kees HovinghNovo Nordisk A/S, Søborg, Denmark; Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Anders Gaarsdal HolstNovo Nordisk A/S, Søborg, Denmark.
Henrik RavnNovo Nordisk A/S, Søborg, Denmark.
A Michael LincoffDepartment of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH. Electronic address: lincofa@ccf.org.
Novo Nordisk (Denmark) · DKCleveland Clinic · USHarvard University · USHCA Midwest Division · USMRC Institute of Genetics and Molecular Medicine · GBNational Institute for Health Research · GBNorthwestern University · USPennington Biomedical Research Center · USSouthwestern Medical Center · USUniversity of Washington · USVA Puget Sound Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has been widely appreciated that obesity is a major risk factor for CVD, treatments that produce effective, durable weight loss and the impact of weight reduction in reducing cardiovascular risk have been elusive. Instead, progress in CVD risk reduction has been achieved through medications indicated for controlling lipids, hyperglycemia, blood pressure, heart failure, inflammation, and/or thrombosis. Obesity has been implicated as promoting all these issues, suggesting that sustained, effective weight loss may have independent cardiovascular benefit. GLP-1 receptor agonists (RAs) reduce weight, improve glycemia, decrease cardiovascular events in those with diabetes, and may have additional cardioprotective effects. The GLP-1 RA semaglutide is in phase 3 studies as a medication for obesity treatment at a dose of 2.4 mg subcutaneously (s.c.) once weekly. Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) is a randomized, double-blind, parallel-group trial testing if semaglutide 2.4 mg subcutaneously once weekly is superior to placebo when added to standard of care for preventing major adverse cardiovascular events in patients with established CVD and overweight or obesity but without diabetes. SELECT is the first cardiovascular outcomes trial to evaluate superiority in major adverse cardiovascular events reduction for an antiobesity medication in such a population. As such, SELECT has the potential for advancing new approaches to CVD risk reduction while targeting obesity.

Indexed as

Glucagon-Like PeptidesObesityOverweightCardiotonic AgentsCardiovascular DiseasesClinical Trials, Phase III as TopicDouble-Blind MethodEquivalence Trials as TopicFemaleGlucagon-Like Peptide 1Heart Disease Risk FactorsHumansHypoglycemic AgentsMaleMiddle AgedOutcome Assessment, Health CareCardiotonic AgentsGlucagon-Like Peptide 1Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Identifiers

PMID32916609
OpenAlexW3042751537

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.